Avidity biosciences reports third quarter 2023 financial results and recent highlights

Avidity reported new positive aoc 1001 data at world muscle society (wms) congress in october demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1 (dm1) aoc 1044 receives orphan designation for the treatment of dmd in us and eu avidity remains on track to report data readouts from three clinical development programs – dm1, dmd and fshd – over the next nine months san diego , nov. 8, 2023 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today reported financial results and recent highlights for the third quarter ended september 30, 2023. avidity ended the third quarter of 2023 with cash, cash equivalents and marketable securities totaling $542.6 million.
RNA Ratings Summary
RNA Quant Ranking